Literature DB >> 30246224

A review of the Rapid Response Radiotherapy Program in patients with advanced cancer referred for palliative radiotherapy over two decades.

Yasmeen Razvi1, Stephanie Chan1, Liying Zhang1, May Tsao1, Elizabeth Barnes1, Cyril Danjoux1, Philomena Sousa1, Pearl Zaki1, Erin McKenzie1, Carlo DeAngelis1, Edward Chow2.   

Abstract

INTRODUCTION: The Rapid Response Radiotherapy Program (RRRP) is an outpatient radiotherapy clinic for palliative cancer patients where consultation, planning, and radiation treatment can take place in 1 day, allowing for rapid access to care. The objective of this study was to compare the patient population and overall survival of patients seen in the RRRP from 2014 to 2017 to that of patients seen in 1999.
METHOD: Patient characteristics including sex, primary cancer site, sites of metastases, and Karnofsky Performance Status (KPS) were recorded at each clinic visit. Date of death (DOD) was retrieved from the Patient Care System (PCS) and Excelicare. To show overall survival from the first clinic visit, a Kaplan-Meier overall survival curve was generated in all patients from 2014 to 2017.
RESULTS: Five hundred ninety-six patients were included in the final analysis. Most patients were male (n = 347) with a primary cancer site of the lung (n = 165) and metastases to the bone (n = 475). Actuarial median overall survival was 15.3 months. In 1999, 395 patients were analyzed, in which a primary of the lung (n = 143) and metastases to the bone (n = 277) were the most prevalent. An additional 72 patients in this population had brain metastases. The actuarial median survival of the 1999 population was 4.5 months.
CONCLUSION: The changing patient population in the RRRP has resulted in visible changes in survival. This may reflect differences in the proportion of patients with specific primaries and sites of metastases, as well as improvements in the availability of palliative radiation over the last two decades.

Entities:  

Keywords:  Palliative care; Primary cancer site; Radiotherapy; Sites of metastases; Survival outcome

Mesh:

Year:  2018        PMID: 30246224     DOI: 10.1007/s00520-018-4474-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  4 in total

1.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.

Authors:  Rui-Xue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-05-01

2.  Palliative Thoracic Radiotherapy for Non-Small Cell Lung Cancer in Outpatients: Reasons for Unplanned Hospitalization and Its Impact on Survival.

Authors:  Carsten Nieder; Kristian S Imingen; Ellinor Haukland
Journal:  J Clin Med Res       Date:  2021-03-19

3.  Decreased complement 4d increases poor prognosis in patients with non-small cell lung cancer combined with gastrointestinal lymph node metastasis.

Authors:  Yan Wang; Mengqi Xiang; Huachuan Zhang; Yongda Lu
Journal:  Exp Ther Med       Date:  2022-07-05       Impact factor: 2.751

4.  Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model.

Authors:  Francesco Cellini; Rossella Di Franco; Stefania Manfrida; Valentina Borzillo; Ernesto Maranzano; Stefano Pergolizzi; Alessio Giuseppe Morganti; Vincenzo Fusco; Francesco Deodato; Mario Santarelli; Fabio Arcidiacono; Romina Rossi; Sara Reina; Anna Merlotti; Barbara Alicja Jereczek-Fossa; Angelo Tozzi; Giambattista Siepe; Alberto Cacciola; Elvio Russi; Maria Antonietta Gambacorta; Marta Scorsetti; Umberto Ricardi; Renzo Corvò; Vittorio Donato; Paolo Muto; Vincenzo Valentini
Journal:  Radiol Med       Date:  2021-09-27       Impact factor: 3.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.